Related references
Note: Only part of the references are listed.Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care
Susan A. Olender et al.
CLINICAL INFECTIOUS DISEASES (2021)
Remdesivir and GS-441524 plasma concentrations in patients with end-stage renal disease on haemodialysis
Matthew R. Davis et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
Nanshan Chen et al.
LANCET (2020)
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
Yeming Wang et al.
LANCET (2020)
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
Jason D. Goldman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Remdesivir for the Treatment of Covid-19-Final Report
John H. Beigel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19
Massimo Tempestilli et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
That Escalated Quickly: Remdesivir's Place in Therapy for COVID-19
Matthew R. Davis et al.
INFECTIOUS DISEASES AND THERAPY (2020)
Reply to Yan and Muller, Captisol and GS-704277, but Not GS-441524, Are Credible Mediators of Remdesivir's Nephrotoxicity
Minh Patrick Le et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Captisol and GS-704277, but Not GS-441524, Are Credible Mediators of Remdesivir's Nephrotoxicity
Victoria C. Yan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Removal of Remdesivir's Metabolite GS-441524 by Hemodialysis in a Double Lung Transplant Recipient with COVID-19
Minh Patrick Le et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Factors associated with COVID-19-related death using OpenSAFELY
Elizabeth J. Williamson et al.
NATURE (2020)
Effect of Cumulative Intravenous Voriconazole Dose on Renal Function in Hematological Patients
Takeo Yasu et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries
Paul Y. Kwo et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2017)
Therapeutic drug monitoring and safety of intravenous voriconazole formulated with sulfobutylether -cyclodextrin in haematological patients with renal impairment
Si-Hyun Kim et al.
MYCOSES (2016)
Administration of Voriconazole in Patients With Renal Dysfunction
Dionissios Neofytos et al.
CLINICAL INFECTIOUS DISEASES (2012)
Cyclodextrins in delivery systems: Applications
Gaurav Tiwari et al.
JOURNAL OF PHARMACY AND BIOALLIED SCIENCES (2010)
Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group
R Bellomo et al.
CRITICAL CARE (2004)
Share Paper
